证券代码：000688 证券简称：国城矿业 公告编号：2026-008 国城矿业股份有限公司 关于为参股公司提供担保的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在任何虚假记载、误导性陈述或者重大 遗漏。 一、担保情况概述 国城矿业股份有限公司（以下简称"公司"或"国城矿业"）分别于2026年1月16日、2026年2月3日召开第 十二届董事会第四十八次会议和2026年第一次临时股东会审议通过了《关于为参股公司提供担保暨关联 交易的议案》，同意公司向参股子公司马尔康金鑫矿业有限公司（以下简称"金鑫矿业"）提供总额合计 不超过人民币70,000万元的担保。具体内容详见公司于2026年1月17日和2026年2月4日在指定媒体上披 露的《关于为参股公司提供担保暨关联交易的公告》（公告编号：2026-002）和《2026年第一次临时股 东会决议公告》（公告编号：2026-007）。 近日，金鑫矿业向厦门象屿商业保理有限责任公司（以下简称"厦门象屿"）、深圳象屿商业保理有限责 任公司（以下简称"深圳象屿"）申请保理融资授信额度人民币10,000万元，公司为金鑫矿业上述业务项 下全部债务余额的48%范 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600735 证券简称：ST新华锦（维权） 公告编号：2026-014 山东新华锦国际股份有限公司 关于资金占用责令改正进展暨公司股票可能 停牌的风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●山东新华锦国际股份有限公司（以下简称"公司"）责令改正事项的期限将于2026年2月25日届满。截至 本公告披露日，公司间接控股股东新华锦集团有限公司（以下简称"新华锦集团"）及其关联方累计归还 占用资金0元。公司如未在期限届满前完成整改，公司股票预计将自2026年2月26日起被上交所实施停 牌，停牌期限不超过2个月。提醒投资者充分关注公司股票停牌、被实施退市风险警示等退市相关风 险。 公司于2025年8月25日收到中国证券监督管理委员会青岛监管局（以下简称"青岛证监局"）出具的《关 于对山东新华锦国际股份有限公司、新华锦集团有限公司、张建华采取责令改正措施的决定》 （【2025】11号）（以下简称"《行政监管措施决定书》"），截至2025年半年度 ...

Core Viewpoint - Zhejiang Kangnbei Pharmaceutical Co., Ltd. has received approval from the National Medical Products Administration for the clinical trial of TFA003 tablets, aimed at treating diabetic nephropathy [1][2]. Group 1: Drug Clinical Trial Approval - The drug TFA003 is classified as a traditional Chinese medicine under categories 2.1 and 2.3, with the application for clinical trials focusing on oral administration for diabetic nephropathy [1][2]. - The approval notice indicates that the drug meets the requirements for drug registration and can proceed with clinical trials after refining the trial protocol [1]. Group 2: R&D Status - The company has invested approximately RMB 29.57 million in the research and development of TFA003, which has shown significant efficacy in improving renal function indicators in animal studies [2]. - The drug has the potential to be developed as a new traditional Chinese medicine for diabetic nephropathy, showing improvements in glomerular filtration and renal tubular reabsorption functions [2]. Group 3: Market Situation - There are currently few drugs available for the treatment of diabetic nephropathy in both domestic and international markets, primarily relying on antihyperglycemic and antihypertensive medications [3][4]. - The market for traditional Chinese medicine related to diabetic nephropathy is projected to reach a total sales volume of RMB 27 billion in 2024, reflecting a year-on-year growth of 5.25% [6].

Core Viewpoint - The announcement details the expected daily related transactions for Jiangsu Yunrong Electronic Technology Co., Ltd. in 2026, amounting to 10.5 million RMB, which are deemed normal business operations and do not require shareholder approval [1][2]. Group 1: Daily Related Transactions Overview - The board of directors approved the expected daily related transactions on February 4, 2026, with a total estimated amount of 10.5 million RMB, following legal procedures [1][2]. - The transactions primarily involve selling goods to related parties and leasing premises, including utilities, which align with the company's operational needs and are considered commercially reasonable [2][5]. Group 2: Related Parties and Their Financial Status - Hubei Jiean Di Technology Group Co., Ltd., a related party, holds a 7.9365% stake in Yunrong Technology and has a good financial standing, ensuring its ability to fulfill contractual obligations [3][4]. - The related party's financial data for the last accounting year will be disclosed in the 2025 annual report [3]. Group 3: Transaction Terms and Impact - The pricing for the related transactions will follow fair market principles, ensuring no adverse effects on the company or minority shareholders [5][6]. - The transactions are structured to support the company's business development without compromising its independence or creating dependency on related parties [6].

Core Viewpoint - Shanghai Guijiu Co., Ltd. is facing significant financial challenges, with projected revenue for 2025 expected to be below 300 million yuan, leading to potential delisting risks due to financial criteria outlined in the stock listing rules [2][4]. Financial Performance - The company anticipates a revenue of less than 300 million yuan for the fiscal year 2025, with both net profit and profit before non-recurring items expected to be negative [2][4]. - The company has received a special report from its auditor, Unitaizhenqing, indicating that the audit report for 2024 will likely contain a non-standard opinion due to unresolved issues, which could affect the 2025 financial statements [2][4]. Stock Trading and Delisting Risks - The company's stock has experienced significant volatility, including consecutive trading halts on January 29 and 30, 2026, and a closing price increase of 4.57% on February 4, 2026 [2]. - The stock has been under delisting risk warning since April 23, 2025, and the company has issued multiple announcements regarding the potential for delisting due to financial performance [5][6]. Shareholder Information - The controlling shareholder, Shanghai Guijiu Enterprise Development Co., Ltd., and its concerted parties hold a total of 216,740,245 shares, which represents 64.80% of the company's total share capital, all of which have been judicially frozen [3][6]. - The company has confirmed that there are no undisclosed significant matters related to the controlling shareholder, including major asset restructuring or bankruptcy [3][6]. Regulatory Compliance - The company is required to issue risk warning announcements every 10 trading days until the annual report is disclosed, as per the stock listing rules [5][6]. - The company emphasizes that all investor communications should refer to the official disclosures made in designated media outlets [7].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002903 证券简称：宇环数控 公告编号：2026-004 宇环数控机床股份有限公司 关于审计机构变更项目质量复核人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 宇环数控机床股份有限公司（以下简称"公司"）于2025年4月7日召开了第五届董事会第二次会议和第五 届监事会第二次会议，会议审议通过了《关于拟续聘公司2025年度审计机构的议案》，同意续聘天健会 计师事务所（特殊普通合伙）为公司2025年度财务及内部控制审计机构，聘期1年。上述议案已经于 2025年5月15日召开的公司2024年年度股东大会审议通过。具体内容详见2025年4月9日公司刊登于巨潮 资讯网（www.cninfo.com.cn）上的《关于拟续聘公司2025年度审计机构的公告》（公告编号：2025- 013）。 近日，公司收到了天健会计师事务所出具的《关于变更项目质量复核人的函》，现将具体变更情况公告 如下： 三、本次变更项目质量复核人对公司的影响 一、本次变更项目质量复核人的基本情况 天健会计师事务所作为公司2025年度 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000532 证券简称：华金资本公告编号：2026-006 珠海华金资本股份有限公司 关于持股5%以上股东减持计划实施期限届满暨实施情况的公告 本公司持股5%以上股东力合科创集团有限公司保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 珠海华金资本股份有限公司（以下简称"公司"）于2025年10月17日在巨潮资讯网（www.cninfo.com.cn） 披露了《关于持股5%以上股东减持股份预披露公告》（公告编号：2025-034）：持有公司股份 27,287,224股（约占本公司总股本比例7.92%）的股东力合科创集团有限公司（以下简称"力合科创"）计 划自上述公告披露之日起15个交易日后的3个月内（自2025年11月7日至2026年2月4日，但法律法规禁止 减持的期间除外），以集中竞价和大宗交易方式拟合计减持公司股份不超过10,341,249股（约占本公司 总股本比例3%）。 根据该股东减持计划执行进展，公司于2025年12月13日披露了《关于持股 ...

江西沐邦高科股份有限公司（以下简称"公司"）董事会于近日收到独立董事王婉君女士、非独立董事洪 善建先生的书面辞职报告，具体情况如下： 一、独立董事离任的基本情况 王婉君女士因个人原因，申请辞去公司第五届董事会独立董事职务，同时一并辞去公司审计委员会召集 人职务。辞职后，王婉君女士将不再担任公司任何职务。 证券代码：603398 证券简称：*ST沐邦 公告编号：2026-007 江西沐邦高科股份有限公司 关于公司独立董事、非独立董事辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 洪善建先生因个人原因，申请辞去公司第五届董事会董事职务，同时一并辞去副董事长职务。辞职后， 洪善建先生将不再担任公司任何职务。 洪善建先生辞去董事职务不会导致公司董事会成员人数低于法定最低人数，其辞职申请自送达公司董事 会之日起生效。洪善建先生已按照公司相关规定做好工作交接。公司将按照有关规定，尽快完成空缺董 事的补选工作。 截至本公告披露日，王婉君女士、洪善建先生均未持有公司股份，亦不存在应当履行而未履行的承诺事 项。公司董事会对王婉君女士 ...

Core Viewpoint - The announcement details a new sales agreement between Invesco Great Wall Fund Management Co., Ltd. and Huaxi Securities Co., Ltd. for the distribution of certain funds starting from February 5, 2026 [1]. Group 1: Applicable Funds - The announcement specifies that certain funds managed by Invesco Great Wall will be available for sale through Huaxi Securities [1]. Group 2: Sales Institution Information - The sales institution is Huaxi Securities Co., Ltd., located in Chengdu, Sichuan, with contact details provided for inquiries [2]. - The legal representative of Huaxi Securities is Yang Jiong Yang, and the contact person is Yang Ru [2]. Group 3: Business Operations - Subscription and redemption services are only available during normal subscription periods and specific open days, with details outlined in the fund's legal documents [3]. - A regular investment plan allows investors to set up automatic deductions for fund purchases, with specific rules governed by Huaxi Securities [3]. Group 4: Fee Structure - Investors may benefit from fee discounts for one-time subscriptions or regular investment plans, subject to the arrangements of Huaxi Securities [4]. - The fund has two classes of shares: Class A, which incurs a subscription fee, and Class C, which does not charge a subscription fee but incurs a service fee [6][7]. Group 5: Redemption Policies - There is no minimum redemption amount, but if a redemption results in a balance of less than one share, the remaining shares must be redeemed [8]. - Redemption fees are applicable and decrease with the holding period of the shares [10]. Group 6: Fund Net Asset Value Disclosure - The fund's net asset value will be disclosed at least weekly during the closed period and no later than the next business day after each open day [11]. Group 7: Additional Information - Investors can access the fund's legal documents, including the fund contract and prospectus, through the company's website or sales institutions for detailed information [12].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:002880 证券简称:卫光生物 公告编号:2026-003 深圳市卫光生物制品股份有限公司 关于对外投资的自愿性披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别风险提示： 1.公司本次与有关合作方共同出资设立项目公司，建设深圳市细胞与基因治疗市场化公共服务平台。公 司认缴出资4,000万元，占项目公司股权比例为40%。认缴出资金额占公司最近一期经审计净资产的比 例为1.81%。 2.项目公司设立后将不纳入公司合并报表范围，并严格按照会计准则的相关规定进行会计核算。本次对 外投资对公司当期财务状况及经营成果不会产生重大不利影响。 深圳市卫光生物制品股份有限公司（以下简称公司）于2026年2月3日召开第四届董事会第七次会议，审 议通过了《关于投资建设深圳市细胞与基因治疗市场化公共服务平台的议案》。现将有关情况公告如 下： 一、对外投资概述 公司拟与深圳市深业生物医药产业发展有限公司（以下简称深业生物）、深圳细胞谷生物医药有限公司 （以下简称深圳细胞谷）及深圳赛桥生物创新技术有限公司（以下简 ...